EP2866791A4 - Neuartige zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie - Google Patents

Neuartige zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie

Info

Publication number
EP2866791A4
EP2866791A4 EP13788513.3A EP13788513A EP2866791A4 EP 2866791 A4 EP2866791 A4 EP 2866791A4 EP 13788513 A EP13788513 A EP 13788513A EP 2866791 A4 EP2866791 A4 EP 2866791A4
Authority
EP
European Patent Office
Prior art keywords
cancer therapy
novel compositions
hypertension agents
hypertension
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13788513.3A
Other languages
English (en)
French (fr)
Other versions
EP2866791A1 (de
Inventor
Rakesh Kumar Jain
Yves Boucher
Vikash Pal Singh Chauhan
Benjamin Diop-Frimpong
Stephen Krane
Alan L Crane
Robert Samuel Langer
John D Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Institute of Technology
XTUIT PHARMACEUTICALS Inc
Original Assignee
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/834,094 external-priority patent/US20130287688A1/en
Application filed by General Hospital Corp, XTUIT PHARMACEUTICALS Inc filed Critical General Hospital Corp
Publication of EP2866791A1 publication Critical patent/EP2866791A1/de
Publication of EP2866791A4 publication Critical patent/EP2866791A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13788513.3A 2012-05-07 2013-05-07 Neuartige zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie Withdrawn EP2866791A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643487P 2012-05-07 2012-05-07
US13/834,094 US20130287688A1 (en) 2010-11-18 2013-03-15 Novel compositions and uses of anti-hypertension agents for cancer therapy
PCT/US2013/039901 WO2013169739A1 (en) 2012-05-07 2013-05-07 Novel compositions and uses of anti-hypertension agents for cancer therapy

Publications (2)

Publication Number Publication Date
EP2866791A1 EP2866791A1 (de) 2015-05-06
EP2866791A4 true EP2866791A4 (de) 2016-04-20

Family

ID=49551209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13788513.3A Withdrawn EP2866791A4 (de) 2012-05-07 2013-05-07 Neuartige zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie

Country Status (5)

Country Link
EP (1) EP2866791A4 (de)
AU (2) AU2013259772A1 (de)
CA (1) CA2872652A1 (de)
HK (1) HK1211832A1 (de)
WO (1) WO2013169739A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2774330T3 (es) 2013-04-09 2020-07-20 Massachusetts Inst Technology Polímero de suministro de fármaco y usos del mismo
US20180325813A1 (en) * 2015-11-07 2018-11-15 Ftf Pharma Private Limited Oral solution of ace inhibitors
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2017214337A1 (en) 2016-06-07 2017-12-14 Massachusetts Institute Of Technology Drug delivery polymers and uses thereof
WO2018039577A1 (en) 2016-08-26 2018-03-01 Massachusetts Institute Of Technology Bottlebrush polymers and uses thereof
WO2018067702A1 (en) 2016-10-04 2018-04-12 Massachusetts Institute Of Technology Bottlebrush copolymers and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
EP3558377A1 (de) * 2016-12-23 2019-10-30 Virttu Biologics Limited Krebsbehandlung
US11155674B2 (en) 2017-01-20 2021-10-26 Massachusetts Institute Of Technology Polymerizable sulfonamide compounds and polymers thereof
US11034788B2 (en) 2017-01-20 2021-06-15 Massachusetts Institute Of Technology Polymers and uses thereof
WO2019006425A1 (en) 2017-06-30 2019-01-03 Massachusetts Institute Of Technology IMAGING AGENTS OF BRUSH ARRAY STAR POLYMERS AND USES THEREOF
EP3645530A2 (de) 2017-06-30 2020-05-06 Massachusetts Institute of Technology Verzweigte multifunktionelle makromonomere und verwandte polymere und deren verwendung
EP3645600A1 (de) 2017-06-30 2020-05-06 Massachusetts Institute of Technology Kern-zu-oberfläche-polymerisation zur synthese von sternpolymeren und deren verwendung
WO2019200367A1 (en) 2018-04-13 2019-10-17 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
US10988491B2 (en) 2018-08-17 2021-04-27 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
AU2020278465A1 (en) 2019-05-20 2021-12-09 Dana-Farber Cancer Institute, Inc. Boronic ester prodrugs and uses thereof
WO2021076821A2 (en) 2019-10-16 2021-04-22 Massachusetts Institute Of Technology Brush prodrugs and uses thereof
MX2022005445A (es) 2019-11-06 2022-08-10 Remedy Plan Inc Tratamientos contra el cáncer dirigidos a las células madre cancerosas.
US20210220391A1 (en) 2020-01-10 2021-07-22 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
CA3217380A1 (en) 2021-05-13 2022-11-17 Yushma Bhurruth-Alcor Nampt inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
WO2012068531A2 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458767B1 (en) * 1994-05-04 2002-10-01 The Uab Research Foundation Use of peptides inhibitory for thrombospondin dependent TGF-β activation in the treatment of kidney disease
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP2374458A1 (de) * 2005-03-21 2011-10-12 Vicus Therapeutics SPE 1, LLC Kombination eines ACE Inhibitors und eines NSAID in der Verwendung zur Verbesserung von Kachexie/SIRS
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
EP2078205A2 (de) * 2006-11-09 2009-07-15 Ore Pharmaceuticals Inc. Brustkrebs-screening und behandlungsverfahren
US20090297621A1 (en) * 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
US8238519B2 (en) * 2010-07-12 2012-08-07 Siemens Medical Solutions Usa, Inc. Rotational radiation treatment of moving targets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
WO2012068531A2 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NOGUCHI R ET AL: "Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 22, no. 2, 1 August 2009 (2009-08-01), pages 355 - 360, XP002744523, ISSN: 1021-335X, [retrieved on 20090801], DOI: 10.3892/OR_00000445 *
RHODES DANIEL R ET AL: "AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 106, no. 25, 23 June 2009 (2009-06-23), pages 10284 - 10289, XP002592235, ISSN: 0027-8424, [retrieved on 20090601], DOI: 10.1073/PNAS.0900351106 *
See also references of WO2013169739A1 *

Also Published As

Publication number Publication date
HK1211832A1 (zh) 2016-10-14
AU2018200448A1 (en) 2018-02-15
EP2866791A1 (de) 2015-05-06
CA2872652A1 (en) 2013-11-14
AU2013259772A1 (en) 2014-12-04
WO2013169739A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
EP2640359A4 (de) Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie
HK1213798A1 (zh) 治療性化合物和組合物
PL2818482T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
HK1202253A1 (en) Combination treatment of cancer
HUE045461T2 (hu) Gyógyászati készítmény rák kezelésére
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2688594A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
HK1200739A1 (en) Diagnostic methods and compositions for treatment of cancer
EP2884984A4 (de) Therapeutische zusammensetzungen und verfahren
HK1214128A1 (zh) 癌症的治療
HK1205254A1 (en) Methods of treatment of cancer
EP2806894A4 (de) Verfahren und zusammensetzungen für therapeutika
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
EP2928456A4 (de) Verfahren und zusammensetzungen für die behandlung von krebs
EP2895186A4 (de) Therapeutische zusammensetzungen und zugehörige verfahren
EP2897607A4 (de) Beta-hydrolase-hemmer zur behandlung von krebs
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
GB201217890D0 (en) Treatment of cancer
GB201222952D0 (en) Treatent of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201208296D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHAUHAN, VIKASH, PAL, SINGH

Inventor name: JAIN, RAKESH, KUMAR

Inventor name: LANGER, ROBERT, SAMUEL

Inventor name: DIOP-FRIMPONG, BENJAMIN

Inventor name: BOUCHER, YVES

Inventor name: KRANE, STEPHEN

Inventor name: MARTIN, JOHN. D.

Inventor name: CRANE, ALAN, L.

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160323

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101AFI20160317BHEP

Ipc: A61P 35/00 20060101ALI20160317BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211832

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Owner name: THE GENERAL HOSPITAL CORPORATION

Owner name: XTUIT PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20170711

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181201